Two Phase 3 trials testing the investigational oral therapy fenebrutinib in people with multiple sclerosis (MS) have hit ...

The first trial that will directly compare the safety and efficacy of stem cell transplantation to the best available drugs in the treatment of relapsing multiple sclerosis (MS) has launched. "There ...

Shares of Contineum Therapeutics dipped by the double-digits late Thursday after investors learned of a clinical setback for ...

Biologic drugs are typically given as infusions that can take an hour or longer. The FDA has approved injectable versions of two biologic Roche drugs, one for multiple sclerosis and the other for ...

An insurance company repeatedly denied a Wisconsin woman coverage for a medication her doctor prescribed to treat her ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on several factors, noted John Corboy, MD, of the Rocky Mountain MS Center at the ...

BOSTON (Reuters) - Genzyme Corp presented new data from a trial of its experimental multiple sclerosis drug alemtuzumab on Thursday that continued to show strong efficacy with no new or worsening side ...

BARCELONA, Spain — Annual dosing of rituximab for relapsing-remitting multiple sclerosis (RRMS) was noninferior to the typical dosing schedule of once every 6 months, which could offer a more ...

MS patients with Medicare plans that exclude more drugs have a higher risk of relapse They might not be able to afford the drugs that would work best for them TUESDAY, Aug. 5, 2025 (HealthDay News) — ...

Even women with more severe MS cases are less likely than men to get critical treatments, a new study finds. Women under age 40 with multiple sclerosis are 8 percent less likely than men to receive ...